Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  JCI Insight

• Publication date

  2018-02-08

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1172/jci.insight.98699PMID 29415893PMCID PMC5821210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thymosin α1 represents a potential potent single molecule-based therapy for cystic fibrosis

  2017influential reference
• Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel.

  2016cited by this paper
• Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

  2016cited by this paper
• Production of 3-D Airway Organoids From Primary Human Airway Basal Cells and Their Use in High-Throughput Screening.

  2016cited by this paper
• RNF5, DAB2 and Friends: Novel Drug Targets for Cystic Fibrosis.

  2016cited by this paper
• A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

  2016cited by this paper
• Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

  2015cited by this paper
• A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects

  2015cited by this paper
• Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation

  2015cited by this paper
• Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.

  2015cited by this paper
• Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway

  2015cited by this paper
• Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

  2014cited by this paper
• Cystic fibrosis genetics: from molecular understanding to clinical application

  2014cited by this paper
• Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis.

  2013cited by this paper
• Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle

  2013cited by this paper
• Mechanism-based corrector combination restores ΔF508-CFTR folding and function

  2013cited by this paper
• Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.

  2013cited by this paper
• Human nasal and tracheo-bronchial respiratory epithelial cell culture.

  2013cited by this paper
• Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.

  2012cited by this paper
• Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia

  2012cited by this paper
• CFTR: folding, misfolding and correcting the ΔF508 conformational defect.

  2012cited by this paper
• Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.

  2012cited by this paper
• Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner* ♦

  2012cited by this paper
• Dual Activity of Aminoarylthiazoles on the Trafficking and Gating Defects of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Caused by Cystic Fibrosis Mutations*

  2011cited by this paper
• Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis

  2011cited by this paper
• Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.

  2011cited by this paper
• Rescue of ΔF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway.

  2011cited by this paper
• Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

  2011influential reference
• Imaging CFTR protein localization in cultured cells and tissues.

  2011cited by this paper
• Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

  2009cited by this paper
• From lab to bedside: emerging clinical applications of thymosin alpha 1.

  2009cited by this paper
• Gating of the CFTR Cl− channel by ATP‐driven nucleotide‐binding domain dimerisation

  2009cited by this paper
• Adapting Proteostasis for Disease Intervention

  2008cited by this paper
• Domain interdependence in the biosynthetic assembly of CFTR.

  2007cited by this paper
• Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

  2006cited by this paper
• Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.

  2005cited by this paper
• Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia.

  2005cited by this paper
• Failure of cAMP agonists to activate rescued ΔF508 CFTR in CFBE41o– airway epithelial monolayers

  2005cited by this paper
• The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon.

  2004cited by this paper
• Double Mechanism for Apical Tryptophan Depletion in Polarized Human Bronchial Epithelium1

  2004cited by this paper
• The PDZ-binding Chloride Channel ClC-3B Localizes to the Golgi and Associates with Cystic Fibrosis Transmembrane Conductance Regulator-interacting PDZ Proteins*

  2003cited by this paper
• Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

  2002cited by this paper
• Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-gamma.

  2000cited by this paper
• Role of CFTR in airway disease.

  1999cited by this paper
• Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung.

  1997cited by this paper
• Degradation of CFTR by the ubiquitin-proteasome pathway.

  1995cited by this paper
• Interferon-gamma downregulates CFTR gene expression in epithelial cells.

  1994cited by this paper
• The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells.

  1993cited by this paper
• Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

  1991cited by this paper
• Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

  1991influential reference
• Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

  1990cited by this paper
• Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA

  1989cited by this paper
• Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

  1989cited by this paper
• Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effects

  1989cited by this paper

• Investigating the role of CFTR in human and mouse myometrium

  2024cites this paper
• The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs

  2022cites this paper
• Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing

  2022cites this paper
• CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium

  2022cites this paper
• One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies

  2022cites this paper
• Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives

  2022cites this paper
• Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

  2021cites this paper
• Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides

  2021cites this paper
• Discovery of CFTR modulators for the treatment of cystic fibrosis

  2021cites this paper
• CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

  2020cites this paper
• Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia

  2020cites this paper
• Evaluation of the Genetic Architecture of Cystic Fibrosis

  2020cites this paper
• Thymosins

  2020cites this paper
• Inhaled Biologicals for the Treatment of Cystic Fibrosis

  2019cites this paper
• Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease

  2019cites this paper
• Greater survival despite increased complication rates following lung transplant for alpha-1-antitrypsin deficiency compared to chronic obstructive pulmonary disease.

  2019cites this paper
• Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.

  2019cites this paper
• Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity

  2019cites this paper
• Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits.

  2019cites this paper
• Unmet needs in cystic fibrosis

  2018cites this paper
• Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function

  2018cites this paper
• Cellular proteostasis: a new twist in the action of thymosin α1

  2018cites this paper
• From thymus to cystic fibrosis: the amazing life of thymosin alpha 1

  2018cites this paper
• Inflammation in cystic fibrosis: An update

  2018cites this paper
• Reply to ‘F508del-CFTR is not corrected by thymosin α1’

  2018cites this paper
• Self‐complementary and tyrosine‐mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells

  2018cites this paper